Effects of angiotensin receptor blocker, Candesartan on renal function in type 2 diabetes with chronic kidney disease and hypertension

UMIN ID: UMIN000002049

Registered date:05/06/2009

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: type 2 diabetes with chronic renal disease and hypertention
• Date of first enrollment: 2008/09/01
• Target sample size: 100
• Countries of recruitment: Japan
• Study type: Interventional
• Intervention(s): Patients: Type 2 diabetes with hypertention (SBP>=130 or DBP>=80) and CKD (eGFR:30<, 60>= mL/min/1.73m2)under regular dose of ARB therapy Intervention: prospectively and randomly divided into two groups matched for age, gender, BMI, BP, and eGFR. Patients of Candesartan group received Candesartan 12mg/day instead of regular dose of ARB. Those of CCB group received regular dose of CCB or maximum dose of CCB when the patients have already received regular dose of CCB. If BP is high after intervention, any hypertensive drugs without ARB, CCB, ACEi can be used.

Outcome(s)

• Primary Outcome: eGFR 1 year after intervention
• Secondary Outcome: IMT, blood pressure (ratio of achievement in BP 130/80mmHg) urinary secretion of albumin, 1 year after intervention

Key inclusion & exclusion criteria

• Age minimum: 40years-old
• Age maximum: 80years-old
• Gender: Male and Female
• Exclude criteria: the patients who are not satisfied with key inclusion criteria.

Related Information

• Primary Sponsor: Juntendo University School of Medicine
• Source(s) of Monetary Support: Takeda pharmaceutical